David A. Siegel Zentalis Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 842,600 shares of ZNTL stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
842,600
Previous 889,700
5.29%
Holding current value
$1.1 Million
Previous $2.7 Million
50.32%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding ZNTL
# of Institutions
140Shares Held
60.7MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$18.1 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$4.24 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$3.99 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.67MShares$3.48 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $74.1M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...